Boston Scientific Buyouts Grow R&D, Offer Liquid Exit For Device Start-Ups
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's strategy to engage emerging medical device companies in a variety of collaborative arrangements provides the company an important source of R&D as well as an attractive exit strategy for the device start-ups, according to Frank Grillo, director of new business development.
You may also be interested in...
Innovation Not Forgotten Art For Device Conglomerates - Wharton Panel
Large device companies play a significant role in medical technology innovation, contrary to the somewhat widespread belief that the start-up sector is the primary driver of R&D, Boston Scientific Chairman Peter Nicholas maintained.
Innovation Not Forgotten Art For Device Conglomerates - Wharton Panel
Large device companies play a significant role in medical technology innovation, contrary to the somewhat widespread belief that the start-up sector is the primary driver of R&D, Boston Scientific Chairman Peter Nicholas maintained.
J&J AngioGuard Emboli Capture Device Purchase Portends SMART Bundle
Clinical trials of Johnson & Johnson's SMART stent for carotid revascularization procedures and AngioGuard's emboli capture device could dovetail following J&J's acquisition of the Minneapolis-based start-up, announced July 7.